胰高血糖素样肽-1受体激动剂用于非酒精性脂肪肝病治疗的研究进展

Progress in research on treatment of non-alcoholic fatty liver disease with glucagon-like peptide-1 receptor agonist

近年来,我国非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)患者人数迅速上升,且发病年龄呈低龄化趋势,已逐步成为重要的公共健康问题。但截至2020年底,全球尚无获批用于NAFLD治疗的药物。与此同时,大量研究证明,胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1RA)类药物在调节人体糖脂代谢、改善胰岛素抵抗(insulin resistance,IR)、缓解炎症和氧化应激反应等方面具有良好的疗效,提示其可能成为治疗NAFLD相关疾病的新选择。本文对NAFLD的发病机制、GLP-1RA药物治疗NAFLD的动物和人体试验结果,以及药物可能的作用途径作一综述。

In recent years,the number of patients with non-alcoholic fatty liver disease(NAFLD)in China has increased rapidly,and the age of onset has been declining,indicating that the disease has gradually become an important public health problem.However,by of the end of 2020,there was still no drug approved for NAFLD worldwide.Meanwhile,a large quantity of studies have proved that glucagon-like peptide-1 receptor agonists(GLP-1 RAs)play important roles in regulating glucose and lipid metabolism,relieving insulin resistance(IR),alleviating inflammation and oxidative stress,which may become a new choice for the treatment of NAFLD.This article reviews the pathogenesis of NAFLD,the results of animal test and clinical trials as well as the possible pharmacology of GLP-1 RA in treatment of NAFLD.